Importance of implant technique on risk of major paravalvular leak (PVL) after St. Jude mechanical heart valve replacement: a report from the Artificial Valve Endocarditis Reduction Trial (AVERT) by Englberger, Lars et al.
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
1
4
9
7
9
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
Importance of implant technique on risk of major paravalvular leak (PVL)
after St. Jude mechanical heart valve replacement: a report from the
Artificial Valve Endocarditis Reduction Trial (AVERT)§
Lars Englberger a,*, Hartzell V. Schaff b, W.R. Eric Jamieson c, Elizabeth D. Kennard d,
Kyung A. Im d, Richard Holubkov e, Thierry P. Carrel a, for the AVERT Investigators
aDepartment of Cardiovascular Surgery, Inselspital, University Hospital, Freiburgstrasse, 3010 Berne, Switzerland
bMayo Clinic, Rochester, MN, USA
cUniversity of British Columbia, Vancouver, BC, Canada
dUniversity of Pittsburgh, Epidemiology Data Coordinating Center, Pittsburgh, PA, USA
eUniversity of Utah, Salt Lake City, UT, USA
Received 19 November 2004; received in revised form 2 September 2005; accepted 5 September 2005; Available online 7 November 2005
Abstract
Objective: To examine risk factors for major paravalvular leak (PVL) events after mechanical heart valve replacement. Methods: We
analyzed outcome of 807 patients randomized into the Artificial Valve Endocarditis Reduction Trial (AVERT). The mean follow-up time was 30.6
months and 21 major PVL events were reported. Three additional major PVL events associated with endocarditis were excluded from analysis. All
baseline medical history variables, as well as operative parameters (including use of pledgets and suture technique) were examined using Cox
regression. Results: Major PVL was reported after 11 aortic, 9 mitral, and 1 double valve replacement. 6/404 (1.5%) patients with conventional
valves experienced a major PVL event versus 15/403 (3.7%) in the Silzone group. 10/172 (5.8%) patients with valve suture technique without
pledgets experienced a major PVL event versus 11/635 (1.7%) patients with pledgets. Final multivariable model showed that only suture
technique without pledgets (p = 0.005) was an independent significant risk factor for major PVL events. Silzone cuff showed a strong trend
( p = 0.055). Conclusions: Suture technique without pledgets is an independent significant risk factor for major PVL events. In this study, use of
pledgets during valve replacement had a protective effect against subsequent paravalvular leak, supporting the use of buttress reinforcement for
valve suture. The use of Silzone cuff, although not statistically significant, showed a strong trend as a risk factor.
# 2005 Elsevier B.V. All rights reserved.
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Major paravalvular leak (PVL) after prosthetic heart
valve replacement is a rare but serious complication. The
occurrence of PVL due to prosthetic valve endocarditis
(PVE) is a well-known phenomenon, which is also included
in the diagnostic criteria of PVE [1]. However, PVL may
occur also without definite signs of infection, and recent
studies suggest that minor PVL is a rather common finding.
When assessed by intraoperative transesophageal echo-
cardiography, PVL has been reported in up to 18% of
patients after aortic valve replacement (AVR) and 23% for
mitral valve replacement (MVR) [2—4]. Minor PVL seems to§ Presented at the joint 18th Annual Meeting of the European Association for
Cardio-thoracic Surgery and the 12th Annual Meeting of the European Society
of Thoracic Surgeons, Leipzig, Germany, September 12—15, 2004.
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doi:10.1016/j.ejcts.2005.09.014have a benign prognosis with progression of regurgitation
requiring reoperation in less than 1%, whereas major PVL
leads almost always to reoperation. The prevalence
and risk factors of major PVL have not been well
characterized yet.
The Artificial Valve Endocarditis Reduction Trial (AVERT)
was designed to evaluate the efficacy of the Silzone
(St. Jude Medical, Minneapolis, MN) silver-coated sewing
ring to reduce PVE, based on studies documenting the
safety and efficacy of silver for antimicrobial protection.
This randomized clinical trial, the protocol for which has
been published previously [5], began recruitment of
patients in July 1998. Reports of a higher incidence of
explant due to PVL in the Silzone study arm led to
suspension of patient enrollment in January 2000.
Additionally, the manufacturer voluntarily recalled all
the Silzone valves from the market. Initial results were
published previously [6]. The AVERTcontinues to follow the
807 randomized patients.
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Table 1
Demographics and medical history
Patient cohort (n = 807)The aim of the current analysis using the AVERT database
was to examine risk factors for major PVL after mechanical
heart valve replacement.Mean age (year) 61.3  10.6
Male 58.9
Weight (kg) 77.8  16.8
Height (cm) 168.3  10.4
Body mass index (kg/m2) 27.4  5.0
NYHA functional class
I 8.7
II 40.5
III 42.3
IV 7.9
Ejection fraction
<35% 9.6
36—50% 20.1
>50% 70.3
Hypertension 46.6
Diabetes 14.3
Smoking (current/past) 39.2
Hypercholesterolemia 31.7
Renal failure 5.8
On dialysis 15.2
Angina pectoris 19.8
Coronary artery disease 33.2
Myocardial infarction 9.5
Cardiac arrhythmias 25.9
Syncope 7.4
TIA 2.9
Stroke, CVA, RIND 6.3
Carotid artery disease 4.2
Peripheral vascular disease 4.6
Non-cerebral embolism 1.5
Hemorrhage, bleeding 1.1
Pulmonary hypertension 24.7
Lung disease 10.9
Immunosuppressive therapy 1.1
Active/treated endocarditis 5.5
Endocarditis (inactive) 2.9
Numbers refer to percentages of patients with those characteristics or mean
values and standard deviations. CVA, cerebrovascular accident; RIND, rever-
sible ischemic neurological deficits; TIA, transient ischemic attack.2. Material and methods
2.1. Study protocol
Details of the AVERTstudy design, sample size determina-
tion, and early clinical findings have been presented
previously [5]. Briefly, the AVERTwas designed to determine
whether silver coating of prosthetic valve sewing rings
reduce the risk of PVE. Patients requiring replacement of the
aortic and/or mitral valve with a mechanical prosthesis were
eligible to be randomized in two study arms: patients
receiving a Silzone-coated prosthesis or a conventional
cuffed St. Jude mechanical heart valve. Between July
1998 and January 2000, a total of 807 patients were
randomized at 12 North American and 7 European centers.
Baseline patient information and details of the operative
procedures were collected at the time of surgery. Data were
collected according to a uniform study protocol with
consistent definitions at all sites. Data collection was
monitored on a routine basis by independent study staff.
Approximately 200 variables were reported during hospita-
lization. Further data were collected by the site coordinators
annually by administration of a patient questionnaire
assessing overall health status, medication use, and symp-
toms associated with possible adverse events. Suspected
adverse events are by protocol reported to the AVERT
Coordinating Center (University of Pittsburgh).
2.2. Event definition
A PVL event was collected per study protocol as a non-
structural dysfunction event, defined as any abnormality
resulting in stenosis or regurgitation at the study value that is
not intrinsic to the valve itself. Furthermore, non-structural
dysfunction refers to only those non-structural problems that
result in dysfunction of a study valve exclusive of infection or
thrombosis diagnosed by reoperation, autopsy, or clinical
investigation [7]. According to the protocol ‘‘A paravalvular
leak must be reported as major if it results in reoperation or
reintervention for repair, or explant, or death. If reinterven-
tion is recommended but is refused by the patient, or cannot
be performed due to comorbidity or other reasons, the
paravalvular leak is still reportable as major’’. The
paravalvular leak and hemolysis events as well as any other
non-structural dysfunction events were collected during the
follow-up period for AVERT cohort.
2.3. Patient population
There were 807 patients randomized into the AVERT
study (403 Silzone and 404 conventional). Demographics,
medical history, information about previous cardiovascular
operations, operations performed, intraoperative charac-
teristics, and detailed information about the operative
procedure performed on the whole study cohort are given in
Tables 1—5. As of July 15, 2005 we had a total of 3652 valveyears of follow-up on these patients (1837 years and 1815
years for Silzone and conventional cuffed valves, respec-
tively). A total of 24 reported PVLs met the definition of
major as of July freeze database. Three major PVL events
were preceded by confirmed endocarditis episodes and
these cases were subsequently excluded from the analysis.
In all analyses, we report the results based on these 21
major PVL events. Of these 21 cases, 15 (3.7%) were
reported in Silzone and 6 (1.5%) in conventional cuffed
valves.
2.4. Statistical methods
To investigate the risk factors for major PVL events in the
AVERT trial, all baseline medical history variables, as well as
operative parameters (including use of pledgets and suture
technique), and diseased valve etiology were examined using
Cox regression methods. Patients without major PVL were
censored at the earliest of the last contact date, date of
death, or study valve explant date. All attributes with a trend
( p < 0.25) of univariable association with PVL events were
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Table 4
Intraoperative characteristics
Patient cohort (n = 807)
CPB time (min) 105.9  55.1
Without concomitant procedures 86.7  39.0
With concomitant procedures 132.6  62.7
Aortic cross-clamp time (min) 76.1  41.3
Without concomitant procedures 63.2  30.3
With concomitant procedures 94.0  47.4
Patient received antibiotics 97.9
Cuff dipped in antibiotics 6.8
Suture dipped in antibiotics 3.1
Pledgets dipped in antibiotics 0.3
Numbers refer to percentages of patients with those characteristics or mean
values and standard deviations.
Table 5
Valve characteristics by position
Aortic Mitra
Number of patients 549 333
Valve being replaced
Native 96.5 93.7
Tissue 2.6 4.5
Mechanical 0.9 1.8
Table 2
Previous cardiovascular operations
Patient cohort (n = 807)
Previous cardiovascular surgery
None 77.7
Aortic valve repair 0.5
Aortic valve replacement 2.4
Mitral valve repair 4.2
Mitral valve replacement 2.6
Any valve replacement 4.7
CABG 5.6
Balloon angioplasty 1.4
Permanent pacemaker 2.2
Carotid endarterectomy 1.5
Other surgery 7.3
Prior operations with CPB
None 85.1
One 12.6
Two 2.0
More than two 0.3
Numbers refer to percentages of patients with those characteristics or mean
values and standard deviations. CABG, coronary artery bypass grafting; CPB,
cardiopulmonary bypass.considered for multivariable modeling. Forward stepwise
regression ( p < 0.25 entry criterion) was used to build the
multivariable model, with Silzone forced in. The first-order
interactions of Silzone with other factors were not tested due
to small number of events. Statistical analyses were
performed using SAS 8.02 (Statistical Analysis Software,
SAS Institute, Cary, NC).Table 3
Operations performed
Patient cohort (n = 807)
Implant position
Aortic (total number) 58.7 (474)
Mitral (total number) 32.0 (258)
Double (total number) 9.3 (75)
Type of approach
Full sternotomy 96.5
Partial sternotomy 1.7
Lateral thoracotomy 0.1
Heart port 1.6
Converted to standard 15.4
Urgency of surgery
Elective 90.3
Urgent 9.7
Concomitant surgical procedures
None 58.2
Aortic valve repair 0.0
Mitral valve repair 1.5
Tricuspid valve repair 5.2
Any valve repair 6.7
CABG 26.2
Intra-aortic balloon 1.1
Aortic root enlargement 1.7
Repair VSD 0.4
Repair ASD 0.3
Other procedures 12.8
Numbers refer to percentages of patients with those characteristics or mean
values and standard deviations. CABG, coronary artery bypass grafting; VSD,
ventricular septal defect; ASD, atrial septal defect.3. Results
Major PVL was reported after 11 aortic, 9 mitral, and 1
double valve replacement (Table 6). Concomitant proceduresValve dysfunction
Insufficiency 22.3 50.8
Stenosis 46.7 10.8
Mixed 30.7 38.4
Valve disease etiology
Degenerative myxomatous 52.6 37.2
Rheumatic 21.7 52.0
Infectious 4.9 7.2
Ischemic 1.3 7.2
Congenital 33.2 0.0
Other 5.1 0.0
Valve pathology
Annular dilatation 4.4 10.8
Annular calcification 47.5 19.8
Leaflet perforation 3.8 3.0
Leaflet calcification 74.5 34.8
Leaflet thickening 47.7 54.1
Papillary muscle elongation/rupture — 3.0
Commissural fusion 20.6 29.7
Chordal elongation/rupture — 16.5
Chordal fusion/thickening — 35.7
Other 16.6 25.5
Valve implanted
SJM conventional 48.1 50.5
SJM Silzone 50.5 49.3
Other 1.5 0.2
Suture technique
Simple interrupted 17.5 14.1
Continuous 12.0 5.1
Everted mattress 24.6 39.3
Non-everted mattress 49.7 45.4
Figure of eight 0.2 0.6
Other 0.2 3.0
Pledgets use 75.4 84.1l
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Table 6
Patients with major paravalvular leaka
No. Age Sex Valve
replaced
Valve type Suture Technique Pledgets Urgency
of surgery
Concomitant
surgeryb
Type of
procedure
Days to
explant
Days to
repair
1 71 M Mitral Conventional Non-everted mattress Yes Elective — Full sternotomy — 1561
2 68 F Mitral Silzone Everted mattress Yes Urgent — Full sternotomy 168 —
3 65 M Aortic Silzone Non-everted mattress Yes Urgent — Full sternotomy — —
4 70 F Aortic Silzone Non-everted mattress Yes Elective — Full sternotomy 1902 —
5 59 F Mitral Silzone Continuous No Elective TVR Full sternotomy 77 —
6 46 M Aortic Conventional Everted mattress Yes Elective — Full sternotomy 1407 —
7 67 M Aortic Silzone Non-everted mattress Yes Elective — Full sternotomy 386 —
8 42 F Mitral Conventional Simple interrupted No Elective — Heart port 101 —
9 58 M Aortic Conventional Simple interrupted No Elective CABG Full sternotomy 342 205
10 58 F Aortic Silzone Simple interrupted No Elective — Full sternotomy 1125 —
11 73 F Mitral Silzone Simple interrupted No Elective — Full sternotomy 518 —
12 62 M Aortic Silzone Simple interrupted No Elective CABG Full sternotomy 286 —
13 60 M Mitral Silzone Everted mattress Yes Elective CABG Full sternotomy 646 —
14 52 M Aortic Conventional Non-everted mattress Yes Elective CABG Full sternotomy — 898
15 50 M Aortic Conventional Continuous No Elective — Full sternotomy — 43
16 44 M Aortic Silzone Continuous No Elective — Full sternotomy 133 —
17 71 F Mitral Silzone Everted mattress Yes Elective — Full sternotomy 112 —
18 65 M Double Silzone Non-everted mattress Yes Elective — Full sternotomy 190 —
19 65 F Mitral Silzone Non-everted mattress Yes Elective — Heart port 89 —
20 70 M Aortic Silzone Simple interrupted No Elective — Full sternotomy 401 —
21 72 F Mitral Silzone Continuous No Urgent — Full sternotomy — 77
a Three patients with endocarditis not listed.
b Received coronary artery bypass grafting (CABG) or tricuspid valve repair (TVR).were performed in 4/21, with tricuspid valve repair in one
patient and coronary artery bypass grafting in three
patients, respectively. 20/21 patients had replacement of
the native valve at baseline operation, one patient had
replacement of a mechanical prosthesis. During the follow-
up period, 20/21 patients had reoperation due tomajor PVL,
one patient died. Out of the 20 reoperated patients 4 had
refixation and 16 had explant of the mechanical heart valve
prosthesis with PVL.
Table 7 shows results of the final multivariable model and
the major PVL rate for each predictor. Only suture technique
without pledgets was an independent significant risk factor
for major PVL events. In the whole AVERT study population,
the majority of implanted valves (75.4% in aortic position and
84.1% in the mitral position, respectively) were sutured with
pledget reinforcement using everted or non-everted mat-
tress sutures (Table 5). However, a major PVL event occurred
in 5.8% (10/172) of patients with no pledget use versus only
1.7% (11/635) of patients with pledget use (Table 7). Due toTable 7
Multivariable model and predictors for major PVL
Attribute Hazard ratio 95% CI p value *
Silzone valve
versus conventional
2.5 (0.98, 6.52) 0.055
Use of pledget 0.3 (0.12, 0.69) 0.005
Number of
PVL events
Number of
patients
Percentage
Conventional valve 6 404 1.5
Silzone valve 15 403 3.7
No pledget use 9 172 5.8
Pledget use 9 635 1.7
* Results of the multivariable model.the low number of PVL events we could not detect any
association between valve position and risk of a PVL event. 1/
21 patients was randomized and operated during active
endocarditis, none of the other patients withmajor PVL had a
history of endocarditis at baseline. The majority of patients
(19/21) were operated with a conventional surgical approach
via full sternotomy. At two participating centers, a total of
13/807 patients randomized in AVERT were operated with
minimal invasive approach using a heart port system. 2/13
had major PVL but the number of events was too small to test
its effect on the occurrence of major PVL in an adequate
statistical analysis. The use of Silzone-coated cuff was forced
into the model and we observed that the effect of Silzone did
not reach conventional significance ( p = 0.055).4. Discussion
Using the AVERT database, the present study identifies use
of implant suture technique without pledget reinforcement
as an independent risk factor for major PVL events. Previous
AVERT interim analysis [6] that led to discontinuation of
enrollment and voluntary withdrawal of the Silzone valve
already reported a higher incidence of major PVL in patients
who received a Silzone valve implant compared with a
conventional cuffed mechanical heart valve. However, in this
current analysis there was no strong evidence of the effect of
Silzone on the risk of major PVL when other factors were
taken into account. This study, however, includes data from a
much longer follow-up period than previous results from the
AVERT trial. The early observation of higher incidence of PVL
among Silzone patients is not supported by statistical
evidence in this analysis. Mechanisms responsible for the
development of major PVL in patients with a Silzone valve
have not been well defined. Contradictory findings in other
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single arm studies compared to AVERT) did not show higher
rates of PVL in Silzone valves [8—12]. This conflicting situation
has been reviewed previously [13,14]. It has been suggested
that Silzone coating inhibits normal fibroblast growth into the
prosthetic valve sewing cuff by possible direct toxic effects of
silver to the surrounding tissue; this is supported by the
findings of poor tissue ingrowth and loosening of sutures in
explanted valves [6,15]. In contrast, a recently published
echocardiographic analysis of the majority of patients
randomized into AVERT [16], excluding patients having had
major PVL with consecutive reoperation, did not show
statistical significant differences in the prevalence or severity
of PVL in the Silzone-coated valve compared with the
conventional prosthetic valve. In addition, this echocardio-
graphic analysis showed lower PVL rates (combinedPVL rate of
8.7%) in the AVERT population than those previously reported
in larger series [16]. The current analysis clearly identifies a
strong trend in the total AVERT study cohort of the use of a
Silzonevalveas a risk factor for thedevelopment ofmajor PVL,
with hazard ratio 2.5 although it did not reach conventional
significance (Table 7).
The interesting finding in this study seems to be the
importance of implant technique on risk of major PVL events.
Multivariable modeling showed a highly significant effect
(p = 0.005) with higher PVL event rates in patients without
pledget use at valve sutures. This protective effect against
subsequent major PVL supports the use of buttress reinforce-
ment for valve sutures in aortic andmitral position. A previous
investigation [17] reported a similar result for mitral valve
replacement. In combination with the other risk factor for
major PVL event—the use of Silzone valves—it has been
hypothesized that technique of valve implantation may have
accounted for differences between the Cardiff Embolic Risk
Factor Study (CERFS) and AVERT. CERFS investigators found
significantly higher rates of thromboembolic events in patients
with implanted Silzone valves, but no excess in PVL rates [12].
To date, AVERT follow-up [6] and also other studies [8,10,18]
could not confirm these findings. Interpretation of conflicting
findings in different clinical trials is difficult [13] and a certain
limitation of CERFS seems to be that this is a non-randomized
study and the patient numbers are relatively small compared
to AVERT. Nevertheless, Ionescu and coworkers [12] raised the
interesting idea that mattress sutures with pledget use force
the sewing ring into much firmer contact with the surrounding
tissue than continuous sutures do, even inducing a degree of
pressure necrosis if sutures are overtightened. In addition, it
would be possible that such a firmer initial fixation of the
Silzone valve may enhance possible toxic effects to the
surrounding tissue leading to a higher incidence of PVL rates.
So far, our results do not support this hypothesis; mattress
suture with pledget use had protective effects against major
PVL events in our study cohort.
This study in fact did not find that Silzone was a significant
independent predictor of major paravalvular leak in patients
when they were followed for an extended period. This study
included AVERT patients who were followed out to 5 years
(90% of patients were followed) and the numbers of
additional leaks since the original reports has been very low.
We did not find additional significant predictive factors in
the AVERT database. In particular, valve position, history ofendocarditis, and immunosuppressive therapy at the time of
baseline valve surgery did not significantly elevate the risk
for major PVL event. However, we did not have sufficient
number of events to examine these effects in depth, and
hence the lack of statistical evidence should be interpreted
with caution. Theoretically, the use of minimal invasive
procedures may also elevate the risk of major PVL events. In
the AVERT database, numbers of valves implanted with heart
port systems are too small for adequate statistical analysis.
This database was also limited to patients who had St. Jude
mechanical valves implanted andmay not be generalizable to
other types of artificial valves.
The present analysis is also limited, since other possible
predicting factors for the occurrence of major PVL events are
difficult to evaluate. Despite data regarding the valve disease
etiology and description of the intraoperative findings of
valve pathology (Table 5) collected in the AVERT database,
one may not exclude other confounding factors like annular
tissue condition when the valve is implanted, which is
difficult to assess objectively. Other possible confounding
factors seem to be surgery-related problems at the time of
implant. In addition, the number of sutures used for valve
implantation was not counted. Since the analysis was
performed only in the 21 patients with major PVL events,
current results may also not be extrapolated to the larger
amount of patients who have minor to moderate PVL.Acknowledgement
The Artificial Valve Endocarditis Reduction Trial is
sponsored by St. Jude Medical.
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Dr C. Yankah (Berlin, Germany): Did you have the opportunity to study
histologically the sutures used for the Silzone valve implantation in order to
exclude any chemical reactions which might have been initiated by the Silzone
valve ring to cause suture disruption on and thus a paravalvular leak?
Dr Englberger: We did not have all the histological examinations of the
explanted valves, but there are some anecdotal reports that the tissue
surrounding a Silzone valve seems to be different than the tissue surrounding a
conventional valve. But that is still hypothetical.
Your question gives me also the possibility to look at some limitations of
the trial, because we cannot exclude confounders here. If we have
intraoperative findings like a calcified annulus or weak tissue, that is
difficult to explain or hard to collect in a study. Some other confounders like
the surgeon itself cannot be ruled out in such a trial. There are still only
hypothetical explanations about factors which cause this higher rate of
paravalvular leak in Silzone patients, which was seen only in the AVERT
database.Editorial comment
How much can we do to reach the ideal valve prosthesis?Since the introduction of the first prosthetic heart valve
for orthotopic implantation, by Starr and Edwards in the early
sixties, a countless number of devices have been created,
marketed and used clinically. Many have not stood the test of
time and some even constituted true clinical disasters with
serious consequences for the patients. The most notorious
was the problem of strut fracture of the initial models of the
Björk—Shiley C—C valve, in the 1980s, which caused the
death of many patients and obliged to elective reoperation
for substitution of the prosthesis in many others, and resulted
in a major legal battle and compensation to the patients
which eventually led to the disappearance of the manufac-
turers.
A much more recent problem was that of the St. Jude
Silzone valve (St. Jude Medical, Minneapolis, MN, USA). This
prosthesis was a modification of the original St. Jude valve by
inclusion of a silver-coated sewing ring aiming at reducing
prosthetic valve endocarditis (PVE), based on studies which
documented the safety and efficacy of silver for antimicro-
bial protection. But a significant incidence of early major
paravalvular leak (PVL) events obliged withdrawal of the
valve from the market.
In a paper published in this issue of the journal, Englberger
et al. [1] proposed to examine the risk factors for major PVL
events after heart valve replacement with the Silzone valve.
To this end, the authors of this multi-institutional study
analysed the late outcome of 807 patients randomised into
the Artificial Valve Endocarditis Reduction Trial (AVERT).
Twenty-one major PVL were reported (11 after aortic, 9 after
mitral, and 1 after double valve replacement). Six of the 404
(1.5%) patients who received conventional valves experi-
enced a major PVL event versus 15/403 (3.7%) in the Silzone
group. The incidence was much higher (10/172; 5.8%) in
patients with non-pledget valve suture technique versus thatin the patient group with pledgeted sutures (11/635; 1.7%).
The final multivariable model showed that only suture
technique without pledgets was an independent significant
risk factor for major PVL events, while the Silzone cuff
‘‘showed a strong trend’’ towards statistical significance.
They thus conclude that the high incidence of unfavourable
events associated with the Silzone valve was not associated
exclusively to the modified sewing ring.
The AVERTclinical randomised trial was designed precisely
to evaluate the efficacy of this prosthesis and began
recruitment of patients in July 1998. Although the initial
results of the trial were published in 2002 [2], reports of a
higher incidence of PVL in the Silzone group led to suspension
of patient enrolment in January 2000 and the manufacturer
voluntarily recalled all the Silzone valves from the market.
Hence, the current report may appear to be of a very limited
interest. The results are fairly well known and the prosthesis
no longer exists, although many patients still live with it, the
vast majority without complications. Since the complication
is easily diagnosed and could be successfully corrected in all
but one of the reported cases, there was no indication for
prophylactic prosthetic replacement. As anything that can be
said about a valve that can no longer be used it is of only
academic importance, this paper can, as one of the reviewers
in the process of evaluation for consideration for publication
put it, be accepted as ‘‘the last and final report on the AVERT
trial’’.
Nonetheless, the AVERT investigators continue to follow
the 807 randomised patients and their late findings may be of
interest for the management of these patients. Because the
number of events registered during the follow-up period was
relatively small (only 20/21 patients had reoperation due to
major PVL and one died), this should tranquilise the remaining
patients. It is highly unlikely that the complication that led to
